DEVELOPMENT OF A SUBCUTANEOUS FORMULATION OF CT-P13 (INFLIXIMAB): MAINTENANCE SUBCUTANEOUS ADMINISTRATION MAY ELICIT LOWER IMMUNOGENICITY COMPARED TO INTRAVENOUS TREATMENT

Shomron Ben-Horin  1     Walter Reinisch  2     Byong Duk Ye  3     Rene Westhovens  4     Dae Hyun Yoo  5     Sang Joon Lee  6     Sung Young Lee     Mi Rim Kim     Stefan Schreiber    
1 University of Tel Aviv Sheba Medical Center,Tel-Hashomer,Israel
2 Medical University Vienna,Vienna,Austria
3 University of Ulsan College of Medicine, Asan Medical Center,Seoul,Korea (Republic of)
4 University Hospital KU Leuven,Leuven,Belgium
5 Hospital for Rheumatic Diseases Hanyang University,Seoul,Korea (Republic of)
6 CELLTRION, INC.,I

Conference
UEG Week 2018

Citation
United European Gastroenterology Journal 2018; 6 (Supplement 1)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing